For Patients and Public
Delve into essential information and heighten your awareness about relevant topics, organizations, general news, and the latest updates on projects
RELEVIUM: EU-Funded Project
Type of Action
HORIZON Research and Innovation Actions
Granting authority: European Health and Digital Executive Agency. Grant managed through EU Funding & Tenders Portal.
1 September 2022 - 31 August 2026 (48 months)
Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Germany
Discover and Learn
Why the Relevium project matters
Pancreatic cancer (PDAC), has the lowest survival rate among all cancers, causing 95,000 deaths each year in the EU.
The RELEVIUM project is dedicated to addressing the challenges of PDAC and improving the quality of life for patients.
To reduce pain and improve the well-being of advanced pancreatic cancer patients by focusing on personalized nutrition, physical activity, and pain management strategies alongside chemotherapy.
This holistic approach aims to empower patients and make their lives less burdensome during this challenging period.
How we'll achieve this
We utilize wearable technology and AI-driven health services. Our solutions collect important health data and present it on a dashboard accessible to patients and clinicians. Through continuous remote monitoring, we track pain levels, estimate muscle mass, monitor nutrition, and assess physical activity.
A five-centre randomized clinical trial (RELEVIUM-RCT) will evaluate the efficacy of the proposed personalized care plans for advanced pancreatic cancer patients. The trial will investigate their impact on quality of life (QoL), cost-effectiveness, health equity, and the stress burden on patient families. The study outcomes will provide recommendations for integrating remote monitoring and improving QoL outcomes in palliative care for advanced pancreatic cancer.
Anders' Story: Insights from a Pancreatic Cancer Patient
Anders Bovin's story is a remarkable account shared by a pancreatic cancer patient who offers valuable insights into the challenges and triumphs of his journey.
His personal narrative sheds light on the realities faced by pancreatic cancer patients and the significance of the Relevium project's mission in supporting individuals like Anders.
By delving into his story, we gain profound insights into the complexities of living with pancreatic cancer and the impact that research and advancements can have on patients' lives. Anders' story serves as a testament to the importance of ongoing efforts in understanding and addressing this devastating disease.
My most important message for this journey is to try to be hopeful, optimistic, and very informed about the illness.
Established in 2003, the European Cancer Patient Coalition (ECPC) represents diverse cancer patient groups across Europe. It advocates for timely and affordable access to optimal treatment and care, while emphasizing the importance of involving patients as partners in addressing cancer-related issues. ECPC provides a platform for information exchange and best practice sharing among European cancer patients.
Founded in 1965, the EPC has grown into a leading professional platform uniting basic scientists and clinicians. It is dedicated to supporting and serving pancreatologists globally, focused on advancing pancreatic knowledge through projects like its annual scientific meeting, webinars, collaborative guidelines, publications, and the renowned post-graduate program, Pancreas 2000.
The DPC eV, a consortium of German-speaking scientists, is dedicated to advancing pancreatic research. Their focus spans promoting collaboration, organizing an annual scientific meeting, supporting joint projects, and nurturing young talent. Key to their mission is facilitating information exchange on pancreas physiology and pathophysiology.